Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surabgene lomparvovec - REGENXBIO

Next Previous
Drug Profile

Surabgene lomparvovec - REGENXBIO

Alternative Names: ABBV-RGX-314; RGX-314; Sura-vec - REGENXBIO

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator REGENXBIO
  • Developer AbbVie; REGENXBIO
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic macular oedema; Diabetic retinopathy
  • No development reported Retinal disorders

Most Recent Events

  • 06 Oct 2025 REGENXBIO completes enrolment in its phase II/III ATMOSPHERE trial for Wet age-related macular degeneration (Treatment-experienced) in USA (Ophthalmic) (NCT04704921)
  • 06 Oct 2025 REGENXBIO completes enrolment in its phase III ASCENT trial for Wet age-related macular degeneration (Treatment-experienced) in United Kingdom, Spain, Japan, Italy, Hungary, Germany, France (Ophthalmic) (NCT05407636)
  • 07 Aug 2025 Adverse events data from a phase IIb/III trial in Diabetic retinopathy released by REGENXBIO

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top